Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.

@article{Zheng2015PreclinicalEO,
  title={Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.},
  author={Bing Qing Zheng and Jia-hui Mao and Lin Qian and Hua Zhu and Dong-hua Gu and Xiao-Dong Pan and Fang Yi and Dong-mei Ji},
  journal={Cancer letters},
  year={2015},
  volume={357 2},
  pages={468-75}
}
Here we found that dual mTORC1/2 inhibitor AZD-2014 significantly inhibited RCC cell survival and growth, with higher efficiency than conventional mTORC1 inhibitors rapamycin and RAD001. RCC cell apoptosis was also induced by AZD-2014. AZD-2014 disrupted mTORC1/2 assembly and activation, while downregulating HIF-1α/2α and cyclin D1 expressions in RCC cells. Meanwhile, AZD-2014 activated autophagy, detected by p62 degradation, Beclin-1/ATG-5 upregulation and light LC3B-I/-II conversion… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Kaelin, Role of VHL genemutation in human cancer

  • W.G.W.Y. Kim
  • J. Clin. Oncol
  • 2004
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…